MAAT Pharma
MAAT.PA$134M
Micro CapEuronext ParisBiotechnology🇫🇷Europe65 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Oct 31, 2026
33wMarket Overview
Stock performance and key metrics
MAAT.PA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
MaaT013
Acute Graft Versus Host Disease in Intestine
Autologous Fecal Microbiota Transplantation
Leukemia, Myeloid, Acute
Pooled allogeneic fecal microbiotherapy
Transplant Complication
fecal microbiota transfer
Fecal Microbiota Transplantation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MaaT013 | Phase 3 | Acute Graft Versus Host Disease in Intestine | - | - |
Autologous Fecal Microbiota Transplantation | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Pooled allogeneic fecal microbiotherapy | Phase 2 | Transplant Complication | - | - |
fecal microbiota transfer | Phase 2 | Fecal Microbiota Transplantation | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply